TIDMABDX

RNS Number : 6693A

Abingdon Health PLC

26 September 2022

Abingdon Health plc

("Abingdon" or "the Company")

Director/PDMR Dealing

York, U.K. 26 September 2022: Abingdon Health plc (AIM: ABDX), a leading international developer and manufacturer of high quality and effective rapid tests, announces that, in addition to the Director Dealing announced on 16 September 2023 ( https://polaris.brighterir.com/public/abingdon_health/news/rns/story/w6zdykr ), on 23 September 2022, Chris Yates, Chief Executive Officer purchased a total of 125,000 ordinary shares of 0.25 pence each ("Ordinary Shares") over two trades (the "Purchases") at a price of 7.3 pence per Ordinary Share. Further to the Purchases, the interest of Chris Yates in the Company is as follows:

 
 Director       Previous number          Number of          Number of             Percentage 
                    of Ordinary    Ordinary Shares    Ordinary Shares            of Ordinary 
                    Shares held          Purchased     held following            Shares held 
                                                            Purchases    following Purchases 
 Chris Yates          7,763,844            125,000          7,888,844                  6.48% 
 

Concert Party

Further to the disclosures in the Company's Admission Document published 11 December 2020 ("Admission Document"), Chris Yates is a member of a concert party (the "Concert Party"). As a result of the Purchases, the aggregate number of Ordinary Shares held by the Concert Party has increased from 42,861,888 to 42,986,888, representing an increase from 35.21 per cent. to 35.32 per cent. of the issued share capital of the Company.

The Purchases were effected under the terms of Note 11 on Rule 9.1 of the Code and therefore have no consequences under the Takeover Code.

As set out in the Company's Admission Document, Chris Yates also holds 392,695 options over Ordinary Shares. It was agreed with the Panel prior to the Company's initial public offering that an obligation under Rule 9 will not arise as a result of the issue of new Ordinary Shares to members of the Concert Party following the exercise of those options referred to above, without the requirement to seek the approval of independent shareholders.

The Concert Party could therefore come to hold in aggregate up to 43,379,513 Ordinary Shares (following the exercise of all options held by its members only), representing a maximum potential interest of up to 35.64 per cent. of the enlarged share capital (as enlarged by such exercise).

Details of the transactions undertaken can be found in the Notification of Dealing Form below.

Enquiries:

 
 Abingdon Health plc                                   www.abingdonhealth.com/investors/ 
 Chris Yates, Chief Executive Officer                                    Via Walbrook PR 
 Melanie Ross , Chief Financial Officer 
 Dr Chris Hand, Non-Executive Chairman 
 
 Singer Capital Markets (Sole Broker and                        Tel: +44 (0)20 7496 3000 
  Nominated Adviser) 
 Peter Steel, Alex Bond, Sam Butcher (Corporate 
  Finance) 
 Tom Salvesen (Corporate Broking) 
 
 Walbrook PR Limited                 Tel: +44 (0)20 7933 8780 or abingdon@walbrookpr.com 
 Phillip Marriage / Alice                     Mob: +44 (0)7867 984 082 / +44 (0)7407 804 
  Woodings                                                                           654 
 
 
 

About Abingdon Health plc

Abingdon Health is a world leading developer and manufacturer of high-quality lateral flow rapid tests across all industry sectors, including healthcare and COVID-19. Abingdon is the partner of choice for a growing global customer base and takes projects from initial concept through to routine and large-scale manufacturing and has also developed and marketed its own labelled tests.

The Company offers product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format. Abingdon Health aims to support the increase in need for rapid results across many industries and locations and produces lateral flow tests in areas such as infectious disease, clinical testing including companion diagnostics, animal health and environmental testing. Faster access to results allows for rapid decision making, targeted intervention and can support better outcomes. This ability has a significant role to play in improving life across the world. To support this aim Abingdon Health has also developed AppDx(R) , a customisable image capturing technology that transforms a smartphone into a self-sufficient, standalone lateral-flow reader.

Founded in 2008, Abingdon Health is headquartered in York, England.

For more information visit: www.abingdonhealth.com

.

 
 1     Details of the person discharging managerial responsibilities 
        / person closely associated 
 a)    Name                                            Chris Yates 
      ----------------------------------------------  ------------------------------------------------------- 
 2     Reason for the notification 
      ------------------------------------------------------------------------------------------------------- 
 a)    Position/status                                 Chief Executive Officer 
      ----------------------------------------------  ------------------------------------------------------- 
 b)    Initial notification                            Initial Notification 
        /Amendment 
      ----------------------------------------------  ------------------------------------------------------- 
 3     Details of the issuer, emission allowance market participant, 
        auction platform, auctioneer or auction monitor 
      ------------------------------------------------------------------------------------------------------- 
 a)    Name                                            Abingdon Health plc 
      ----------------------------------------------  ------------------------------------------------------- 
 b)    LEI                                             213800XFI4WV3FBILO20 
      ----------------------------------------------  ------------------------------------------------------- 
 4     Details of the transaction(s): section to be repeated for 
        (i) each type of instrument; (ii) each type of transaction; 
        (iii) each date; and (iv) each place where transactions 
        have been conducted 
      ------------------------------------------------------------------------------------------------------- 
 a)    Description of the                              Ordinary Shares of 0.025 pence each 
        financial instrument, 
        type of instrument 
 
       Identification code                             GB00BLF79J41 
 
 b)    Nature of the transaction                                  Purchase of Ordinary Shares 
      ----------------------------------------------  ------------------------------------------------------- 
 c)    Price(s) and volume(s) 
                                                       ----------------------------------------  ---------- 
                                                        Price(s)                                  Volume(s) 
                                                       ----------------------------------------  ---------- 
    7.3 pence                                                                                     50,000 
   --------------------------------------------------------------------------------------------  ---------- 
    7.3 pence                                                                                     75,000 
   --------------------------------------------------------------------------------------------  ---------- 
 
 d)    Aggregated information                            Total volume: 125,000 Ordinary 
                                                          Shares 
                                                          Price: 7.3 pence per Ordinary Share 
 
 e)    Date of the transaction                         23 September 2022 
      ----------------------------------------------  ------------------------------------------------------- 
 f)    Place of the transaction                                   London Stock Exchange, AIM 
      ----------------------------------------------  ------------------------------------------------------- 
 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHLQLFLLKLLBBZ

(END) Dow Jones Newswires

September 26, 2022 08:26 ET (12:26 GMT)

Abingdon Health (LSE:ABDX)
Historical Stock Chart
From Oct 2022 to Nov 2022 Click Here for more Abingdon Health Charts.
Abingdon Health (LSE:ABDX)
Historical Stock Chart
From Nov 2021 to Nov 2022 Click Here for more Abingdon Health Charts.